Loading clinical trials...
Loading clinical trials...
Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma
Conditions
Interventions
Off Drug Surveillance
Locations
5
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Columbia University
New York, New York, United States
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States
Thomas Jefferson University, Honickman Center
Philadelphia, Pennsylvania, United States
Start Date
July 5, 2023
Primary Completion Date
June 1, 2026
Completion Date
January 1, 2027
Last Updated
October 1, 2025
NCT07236021
NCT06418750
NCT04236063
NCT04364724
NCT03607643
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions